AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25616350 — intervention group
Group type: COMPARATOR
Intervention: Dye cholangiogram
Number of subjects: 49
Study 21776838 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of liquid culture of Neocallimastix sp. CF 17 (about 10(6) TFU/ml)
Number of subjects: 18
Study 21776838 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated culture of Neocallimastix sp. CF 17
Number of subjects: 18
Study 21776838 — intervention group
Group type: COMPARATOR
Intervention: Control (200 ml of autoclaved culture)
Number of subjects: 18
Study 19755186 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management (SM) telehealth intervention
Number of subjects: 232
Study 19755186 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 232
Study 19755186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SM intervention and usual care)
Number of subjects: 232
Study 17162194 — intervention group
Group type: EXPERIMENTAL
Intervention: multilevel botulinum toxin A and comprehensive rehabilitation
Number of subjects: 46
Study 15638049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 13
Study 15638049 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 13
Study 15638049 — intervention group
Group type: COMPARATOR
Intervention: Control (US examination)
Number of subjects: 13
Study 11522112 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread enriched with plant sterols (1.6 g/day)
Number of subjects: 53
Study 11522112 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched control spread
Number of subjects: 53
Study 11522112 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol margarine in patients treated with fibrates
Number of subjects: 53
Study 11522112 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol margarine in patients not treated with fibrates
Number of subjects: 53
Study 9684633 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets (IIBNs)
Number of subjects: 862
Study 9684633 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of permethrin-impregnated bed nets (IIBNs)
Number of subjects: 862
Study 8143448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive application of Duraphat varnish (three applications during 1 week, once a year)
Number of subjects: 134
Study 8143448 — intervention group
Group type: COMPARATOR
Intervention: Control group (one application at the annual check-up)
Number of subjects: 134
Study 3258124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 0
Study 3258124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 0
Study 3258124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31968642 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games (exergaming)
Number of subjects: 0
Study 31182054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise group
Number of subjects: 180
Study 31182054 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to high-intensity exercise group
Number of subjects: 180
Study 31182054 — intervention group
Group type: COMPARATOR
Intervention: Control non-exercise group
Number of subjects: 180
Study 26756502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg, 2 mL)
Number of subjects: 90
Study 26756502 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 mL)
Number of subjects: 90
Study 25885409 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of low dose Iohexol (CILDI) at 0.5 mL/h for 12 h
Number of subjects: 17
Study 25885409 — intervention group
Group type: COMPARATOR
Intervention: Single bolus of Iohexol (SBI)
Number of subjects: 17
Study 24218874 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley flake (BF)
Number of subjects: 100
Study 24218874 — intervention group
Group type: COMPARATOR
Intervention: Oat meal (OM)
Number of subjects: 100
Study 21836140 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 12
Study 21836140 — intervention group
Group type: COMPARATOR
Intervention: Control (no compression stockings)
Number of subjects: 12
Study 18775538 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 25131
Study 18775538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25131
Study 17878117 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (stimulus control instructions, sleep restriction, and sleep education and hygiene)
Number of subjects: 72
Study 17878117 — intervention group
Group type: COMPARATOR
Intervention: Single‐component control group (sleep education and hygiene)
Number of subjects: 72
Study 17878117 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 72
Study 17878117 — intervention group
Group type: COMPARATOR
Intervention: Single‐component control group
Number of subjects: 72
Study 17878117 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 15475831 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50 mg/d)
Number of subjects: 21
Study 15475831 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (20 mg/d)
Number of subjects: 21
Study 15475831 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 12062537 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran (1.5‐6 mg bid) in poloxamer depot formulation
Number of subjects: 170
Study 12062537 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran (2‐4 mg bid) in saline or as a depot formulation in cyclodextrin
Number of subjects: 170
Study 10197945 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy intervention
Number of subjects: 103
Study 10197945 — intervention group
Group type: COMPARATOR
Intervention: Conventional model of care
Number of subjects: 103
Study 7594671 — intervention group
Group type: EXPERIMENTAL
Intervention: 3, 10, or 30 micrograms of OspA vaccine
Number of subjects: 30
Study 7594671 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of OspA vaccine
Number of subjects: 30
Study 2150644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5mg twice daily
Number of subjects: 64
Study 2150644 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard 20mg twice daily
Number of subjects: 64
Study 2150644 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 64
Study 533222 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.1 mg/10 kg (A)
Number of subjects: 342
Study 533222 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.1 mg/10 kg and diazepam 5 mg (AD)
Number of subjects: 342
Study 533222 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.1 mg/10 kg and fentanyl 0.2 mg (AF)
Number of subjects: 342
Study 533222 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.1 mg/10 kg, diazepam 5 mg and fentanyl 0.2 mg (ADF)
Number of subjects: 342
Study 533222 — intervention group
Group type: COMPARATOR
Intervention: Atropine (A) or Atropine and Diazepam (AD)
Number of subjects: 342
Study 31843420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (9-week protocol with 4 sessions before and 7 sessions after surgery)
Number of subjects: 96
Study 31843420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 96
Study 31843420 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery only)
Number of subjects: 96
Study 31428750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft without a collagen membrane (TG)
Number of subjects: 19
Study 31428750 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived xenograft with a collagen membrane (CG)
Number of subjects: 19
Study 28338546 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50-200 mg/d)
Number of subjects: 19
Study 28338546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 25889066 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept map study
Number of subjects: 91
Study 25889066 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-explanation
Number of subjects: 91
Study 25889066 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept map completion
Number of subjects: 91
Study 22983839 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 200
Study 22983839 — intervention group
Group type: COMPARATOR
Intervention: White light gastroscopy (WLG)
Number of subjects: 200
Study 21353308 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable condition
Number of subjects: 0
Study 21353308 — intervention group
Group type: COMPARATOR
Intervention: Unreliable condition
Number of subjects: 0
Study 19622188 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-based cheese (45.97 mg isoflavones) taken once a day for 10 days under Western diet
Number of subjects: 24
Study 19622188 — intervention group
Group type: COMPARATOR
Intervention: Chronic intake of soya-based cheese under Western diet
Number of subjects: 24
Study 17194961 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 0
Study 17194961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 0
Study 17194961 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 0
Study 17194961 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 0
Study 17194961 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo
Number of subjects: 0
Study 17194961 — intervention group
Group type: COMPARATOR
Intervention: Valerian
Number of subjects: 0
Study 15112863 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (10 mg/2 tablets)
Number of subjects: 8
Study 11529630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with systemic sclerosis (SS)
Number of subjects: 23
Study 11529630 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 9332682 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during the follicular phase (n = 358)
Number of subjects: 1033
Study 9332682 — intervention group
Group type: COMPARATOR
Intervention: Surgery during the luteal phase (n = 675)
Number of subjects: 1033
Study 9332682 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during the follicular phase for ER-negative primaries (n = 300)
Number of subjects: 1033
Study 9332682 — intervention group
Group type: COMPARATOR
Intervention: Surgery during the luteal phase for ER-negative primaries (n = 300)
Number of subjects: 1033
Study 8187784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg orally twice a day for 7 days)
Number of subjects: 42
Study 8187784 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (3 g parenterally per day for 7 days)
Number of subjects: 42
Study 3959571 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micron nylon screen filter in the arterial line (Group 1)
Number of subjects: 100
Study 3959571 — intervention group
Group type: COMPARATOR
Intervention: No filter used in the arterial line (Group 2)
Number of subjects: 100
Study 30865001 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone 0.11 mg/kg (D1 group)
Number of subjects: 66
Study 30865001 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administered intravenous dexamethasone 0.11 mg/kg and intravenous dexmedetomidine 1.0 μg/kg (D2 group)
Number of subjects: 66
Study 30865001 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 0.9% saline (control)
Number of subjects: 66
Study 30865001 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 and D2 groups (both dexamethasone)
Number of subjects: 66
Study 28082116 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleroligation
Number of subjects: 120
Study 28082116 — intervention group
Group type: COMPARATOR
Intervention: Band ligation
Number of subjects: 120
Study 25547035 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy monitoring
Number of subjects: 93
Study 23962259 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, home-based, personalized program
Number of subjects: 100
Study 23962259 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 100
Study 21423112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 0
Study 21423112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19207621 — intervention group
Group type: EXPERIMENTAL
Intervention: ERASE-Stress intervention (ES) consisting of 12 classroom sessions lasting 90 minutes each, including psycho-educational material, skill training, and resiliency strategies.
Number of subjects: 114
Study 19207621 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (WL)
Number of subjects: 114
Study 17941584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of botulinum toxin A (BTX‐A) every 3 months to adductors, medial hamstrings, and psoas muscles
Number of subjects: 67
Study 17941584 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control Group B)
Number of subjects: 67
Study 15799592 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling and the quit line's stop‐smoking booklet, which included information on ingredients found in cigarettes.
Number of subjects: 0
Study 15799592 — intervention group
Group type: COMPARATOR
Intervention: Telephone counseling and the quit line's stop‐smoking booklet plus a basic brochure with a generic cover.
Number of subjects: 0
Study 15799592 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling and the quit line's stop‐smoking booklet plus a brochure targeted to individual cigarette brand and type.
Number of subjects: 0
Study 15799592 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (regardless of brochure type).
Number of subjects: 0
Study 15799592 — intervention group
Group type: EXPERIMENTAL
Intervention: Those who reported reading some or all of the brochure.
Number of subjects: 0
Study 11717595 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized CVD treatments according to current guidelines
Number of subjects: 400
Study 11717595 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 9164196 — intervention group
Group type: COMPARATOR
Intervention: Standard AC therapy (4 courses)
Number of subjects: 2305
Study 9164196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy (same total dose in 2 courses)
Number of subjects: 2305
Study 9164196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified and increased therapy (total dose doubled)
Number of subjects: 2305
Study 7904106 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g)
Number of subjects: 34
Study 7904106 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment (placebo)
Number of subjects: 34
Study 3552906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg tid for two weeks)
Number of subjects: 12
Study 3552906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2713990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple stimulation for 45 minutes three times a day for three days
Number of subjects: 60
Study 2713990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 31169350 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment AOBPM DBP range of 68.6-78.6 mm Hg
Number of subjects: 1470
Study 31169350 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical composite endpoint
Number of subjects: 1470
Study 28378342 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (12 supervised weekly sessions of 90 min; n=39)
Number of subjects: 77
Study 28378342 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (n=39)
Number of subjects: 77
Study 28378342 — intervention group
Group type: COMPARATOR
Intervention: Written self-care advice (n=38)
Number of subjects: 77
Study 25465484 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) technique
Number of subjects: 20
Study 25465484 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 20
Study 25465484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AR and Conventional)
Number of subjects: 20
Study 23875821 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Intervention Group (IIG)
Number of subjects: 600
Study 23875821 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention Group (DIG)
Number of subjects: 600
Study 21561033 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal matrix system (100 microg/h)
Number of subjects: 74
Study 21561033 — intervention group
Group type: COMPARATOR
Intervention: Transdermal reservoir system (100 microg/h)
Number of subjects: 74
Study 19236443 — intervention group
Group type: EXPERIMENTAL
Intervention: RHIIP (6.5 mg, 187 IU, inhaled via Cyclohaler DPI)
Number of subjects: 30
Study 19236443 — intervention group
Group type: COMPARATOR
Intervention: SCIns (10 IU subcutaneous)
Number of subjects: 30
Study 16837888 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day (group B)
Number of subjects: 68
Study 16837888 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (group C)
Number of subjects: 68
Study 16837888 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 68
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartz fiber dowel with 1.0 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber dowel with 1.0 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber plus zirconia dowel with 1.0 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia dowel with 1.0 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartz fiber dowel with 1.5 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber dowel with 1.5 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber plus zirconia dowel with 1.5 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia dowel with 1.5 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartz fiber dowel with 2.0 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber dowel with 2.0 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber plus zirconia dowel with 2.0 mm ferrule
Number of subjects: 123
Study 15295325 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia dowel with 2.0 mm ferrule
Number of subjects: 123
Study 10686384 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent higher-pitch 'deviant' tones
Number of subjects: 0
Study 10686384 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent 'standard' tones
Number of subjects: 0
Study 10686384 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended tones (both deviant and standard)
Number of subjects: 0
Study 10686384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignored tones (both deviant and standard)
Number of subjects: 0
Study 9087467 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic group
Number of subjects: 300
Study 9087467 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic group
Number of subjects: 300
Study 8470415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF) 2 mg
Number of subjects: 20
Study 8470415 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (ISR) 0.5 mg
Number of subjects: 20
Study 8470415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (NIS) 0.5 mg
Number of subjects: 20
Study 8470415 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (FEL) 0.6 mg
Number of subjects: 20
Study 8470415 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 20
Study 3715709 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (total dose 66 Gy, single dose 1.8 to 2 Gy, 1 to 2 fractions daily, total treatment period 4 to 5.5 weeks)
Number of subjects: 0
Study 3715709 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation with treatment period of less than four weeks
Number of subjects: 0
Study 3715709 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation with treatment period of more than five weeks
Number of subjects: 0
Study 28975719 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially absorbable lightweight mesh (ULTRAPRO™)
Number of subjects: 85
Study 28975719 — intervention group
Group type: COMPARATOR
Intervention: Multifilament polyester anatomical mesh (Parietex™)
Number of subjects: 85
Study 28975719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meshes
Number of subjects: 85
Study 27049879 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based balance exercises
Number of subjects: 18
Study 27049879 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance exercises
Number of subjects: 18
Study 24654636 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding counseling sessions held at the maternity ward and at home (at 7, 15, 30, 60, and 120 days postpartum)
Number of subjects: 323
Study 24654636 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding counseling sessions
Number of subjects: 323
Study 22979900 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 100
Study 22979900 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 100
Study 20668414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure hemorrhoidectomy (LH)
Number of subjects: 68
Study 20668414 — intervention group
Group type: COMPARATOR
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 68
Study 18606504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10, 20 and 40 mg)
Number of subjects: 9
Study 18606504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone (15, 30 and 45 mg)
Number of subjects: 9